JP2022532850A5 - - Google Patents
Info
- Publication number
- JP2022532850A5 JP2022532850A5 JP2021563175A JP2021563175A JP2022532850A5 JP 2022532850 A5 JP2022532850 A5 JP 2022532850A5 JP 2021563175 A JP2021563175 A JP 2021563175A JP 2021563175 A JP2021563175 A JP 2021563175A JP 2022532850 A5 JP2022532850 A5 JP 2022532850A5
- Authority
- JP
- Japan
- Prior art keywords
- pyridine
- pyrrolo
- tetrahydro
- methoxy
- chloro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962838051P | 2019-04-24 | 2019-04-24 | |
| US62/838,051 | 2019-04-24 | ||
| US201962940036P | 2019-11-25 | 2019-11-25 | |
| US62/940,036 | 2019-11-25 | ||
| PCT/EP2020/061176 WO2020216781A1 (en) | 2019-04-24 | 2020-04-22 | 4h-pyrrolo[3,2-c]pyridin-4-one compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022532850A JP2022532850A (ja) | 2022-07-20 |
| JP2022532850A5 true JP2022532850A5 (cg-RX-API-DMAC7.html) | 2023-04-14 |
| JP7641913B2 JP7641913B2 (ja) | 2025-03-07 |
Family
ID=70456765
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021563175A Active JP7641913B2 (ja) | 2019-04-24 | 2020-04-22 | ４ｈ－ピロロ［３，２－ｃ］ピリジン－４－オン化合物 |
Country Status (26)
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3700904B1 (en) | 2017-10-24 | 2023-07-19 | Bayer AG | 4h-pyrrolo[3,2-c]pyridin-4-one derivatives |
| US12403135B2 (en) | 2019-04-24 | 2025-09-02 | Bayer Aktiengesellschaft | 4H-pyrrolo[3,2-c]pyridin-4-one derivatives |
| CN115836070B (zh) * | 2020-08-10 | 2024-08-09 | 上海和誉生物医药科技有限公司 | 作为egfr抑制剂的稠环化合物及其制备方法和应用 |
| KR20230094197A (ko) * | 2020-09-23 | 2023-06-27 | 스코르피온 테라퓨틱스, 인코퍼레이티드 | 암 치료에 유용한 피롤로[3,2-c]피리딘-4-온 유도체들 |
| WO2022094271A1 (en) * | 2020-10-30 | 2022-05-05 | Scorpion Therapeutics, Inc. | Methods for treating cancer |
| WO2022098992A1 (en) * | 2020-11-05 | 2022-05-12 | Scorpion Therapeutics, Inc. | Use of macrocyclic compounds in methods of treating cancer |
| EP4244225A1 (en) * | 2020-11-11 | 2023-09-20 | Bayer Aktiengesellschaft | N-[2-({4-[3-(anilino)-4-oxo-4,5,6,7-tetrahydro-1h-pyrrolo[3,2-c]pyridin-2-yl]pyridin-3-yl)oxy)ethyl]prop-2-enamide derivatives and similar compounds as egfr inhibitors for the treatment of cancer |
| TW202309022A (zh) | 2021-04-13 | 2023-03-01 | 美商努法倫特公司 | 用於治療具egfr突變之癌症之胺基取代雜環 |
| CN118019534A (zh) * | 2021-05-06 | 2024-05-10 | 细胞基因公司 | 使用n-((r)-1-(3-氯吡啶-2-基)-2,2,2-三氟乙基)-2-((s)-2,6-二氧代哌啶-3-基)-1-氧代异吲哚啉-5-甲酰胺的治疗方法 |
| CA3246654A1 (en) * | 2022-03-24 | 2023-09-28 | Antares Therapeutics, Inc. | METHODS FOR SYNTHESIZING EGFR INHIBITORS |
| US20250282795A1 (en) * | 2022-04-20 | 2025-09-11 | Celyn Therapeutics, Inc. | EGFR Inhibitors in cancer treatment |
| WO2026047022A1 (en) | 2024-08-28 | 2026-03-05 | Bayer Aktiengesellschaft | Stable solid pharmaceutical dosage form comprising crystalline form of her2/mutegfr inhibitor and process for its preparation |
| WO2026047020A1 (en) | 2024-08-28 | 2026-03-05 | Bayer Aktiengesellschaft | Crystalline forms of her2/mutegfr inhibitors and process for their preparation |
| CN119264091B (zh) * | 2024-09-04 | 2025-05-27 | 康龙化成手性医药技术(宁波)有限公司 | 一种1,5-双取代-3-氧杂双环[3.1.1]庚烷的合成方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3966781A (en) | 1970-12-17 | 1976-06-29 | Merck Sharp & Dohme (I.A.) Corporation | Deuteration of functional group-containing hydrocarbons |
| US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
| US6673908B1 (en) * | 1999-02-22 | 2004-01-06 | Nuvelo, Inc. | Tumor necrosis factor receptor 2 |
| US8299108B2 (en) | 2002-03-29 | 2012-10-30 | Novartis Ag | Substituted benzazoles and methods of their use as inhibitors of raf kinase |
| US7211573B2 (en) | 2004-12-08 | 2007-05-01 | Hoffmann-La Roche Inc. | Malonamide derivatives |
| DE102006033140A1 (de) | 2006-07-18 | 2008-01-24 | Merck Patent Gmbh | Aminoindazolharnstoffderivate |
| BRPI0810498A2 (pt) | 2007-04-27 | 2014-10-14 | Sumitomo Chemical Compay Ltd | Composto amida e seu uso |
| ES2424977T3 (es) | 2007-08-08 | 2013-10-10 | Glaxosmithkline Intellectual Property Development Limited | Derivados de 2-[(2-{fenilamino}-1H-pirrolo[2,3-D]pirimidin-4-il)amino]benzamida como inhibidores de IGF-1R para el tratamiento del cáncer |
| TWI491610B (zh) | 2008-10-09 | 2015-07-11 | 必治妥美雅史谷比公司 | 作為激酶抑制劑之咪唑并嗒腈 |
| US8546413B2 (en) * | 2009-06-15 | 2013-10-01 | Nerviano Medical Sciences S.R.L. | Substituted pyrimidinylpyrrolopyridinone derivatives, process for their preparation and their use as kinase inhibitors |
| US8791162B2 (en) | 2011-02-14 | 2014-07-29 | Merck Sharp & Dohme Corp. | Cathepsin cysteine protease inhibitors |
| EP3033342A1 (en) | 2013-08-13 | 2016-06-22 | Grünenthal GmbH | Annelated pyrroles and their use as crac inhibitors |
| JP6468611B2 (ja) * | 2014-05-13 | 2019-02-13 | アリアド ファーマシューティカルズ， インコーポレイテッド | キナーゼ阻害のためのヘテロアリール化合物 |
| EP3157914B1 (en) | 2014-06-17 | 2018-09-26 | Bayer Pharma Aktiengesellschaft | 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones |
| CA2969771A1 (en) | 2014-12-08 | 2016-06-16 | Bayer Pharma Aktiengesellschaft | Novel aryl-cyanoguanidine compounds |
| US10301306B2 (en) | 2014-12-15 | 2019-05-28 | Bristol-Myers Squibb Company | Substituted dihydro-1H-pyrrolo[3,2-c]pyridin-4(5H)-ones as RIPK3 inhibitors |
| TN2017000329A1 (en) * | 2015-01-28 | 2019-01-16 | Bayer Pharma AG | 4h-pyrrolo[3,2-c]pyridin-4-one derivatives |
| EP3700904B1 (en) * | 2017-10-24 | 2023-07-19 | Bayer AG | 4h-pyrrolo[3,2-c]pyridin-4-one derivatives |
-
2020
- 2020-04-22 DK DK20721196.2T patent/DK3959211T3/da active
- 2020-04-22 GE GEAP202015804A patent/GEP20247648B/en unknown
- 2020-04-22 TW TW109113538A patent/TWI849114B/zh active
- 2020-04-22 JO JOP/2021/0285A patent/JOP20210285A1/ar unknown
- 2020-04-22 WO PCT/EP2020/061176 patent/WO2020216781A1/en not_active Ceased
- 2020-04-22 JP JP2021563175A patent/JP7641913B2/ja active Active
- 2020-04-22 US US17/605,975 patent/US20220298157A1/en active Pending
- 2020-04-22 MX MX2021012987A patent/MX2021012987A/es unknown
- 2020-04-22 AU AU2020262221A patent/AU2020262221B2/en active Active
- 2020-04-22 GE GEAP202415804A patent/GEAP202415804A/en unknown
- 2020-04-22 CN CN202080031189.4A patent/CN114127064B/zh active Active
- 2020-04-22 CN CN202311716707.8A patent/CN117986251A/zh active Pending
- 2020-04-22 EP EP20721196.2A patent/EP3959211B1/en active Active
- 2020-04-22 BR BR112021019998-5A patent/BR112021019998B1/pt active IP Right Grant
- 2020-04-22 SG SG11202111304UA patent/SG11202111304UA/en unknown
- 2020-04-22 CA CA3137218A patent/CA3137218A1/en active Pending
- 2020-04-22 PE PE2021001760A patent/PE20220254A1/es unknown
- 2020-04-22 PH PH1/2021/552693A patent/PH12021552693A1/en unknown
- 2020-04-22 KR KR1020217037778A patent/KR102915019B1/ko active Active
- 2020-04-22 FI FIEP20721196.2T patent/FI3959211T3/fi active
- 2020-04-22 MA MA055751A patent/MA55751A/fr unknown
- 2020-04-22 UA UAA202106517A patent/UA130453C2/uk unknown
- 2020-04-22 IL IL287390A patent/IL287390B2/en unknown
- 2020-04-22 CN CN202311714944.0A patent/CN117946100A/zh active Pending
- 2020-04-22 CR CR20210530A patent/CR20210530A/es unknown
-
2021
- 2021-10-19 EC ECSENADI202177614A patent/ECSP21077614A/es unknown
- 2021-10-20 CO CONC2021/0014022A patent/CO2021014022A2/es unknown
- 2021-10-21 CL CL2021002770A patent/CL2021002770A1/es unknown
- 2021-10-22 DO DO2021000216A patent/DOP2021000216A/es unknown
-
2024
- 2024-11-15 US US18/949,801 patent/US20250136599A1/en active Pending